AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 https://ow.ly/FNFs50U2gXr
AbCellera
Biotechnology Research
Vancouver, British Columbia 36,096 followers
Antibody discovery engine
About us
AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.
- Website
-
http://www.abcellera.com
External link for AbCellera
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2012
- Specialties
- Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell engagers, and Bispecifics
Locations
-
Primary
Get directions
2215 Yukon St
Vancouver, British Columbia V5Y, CA
-
Get directions
91 Mystic St
Arlington, Massachusetts 02474, US
-
Get directions
41-45 Bourke Rd
Alexandria, New South Wales 2015, AU
-
Get directions
7236 Rue Waverly
Montreal, Quebec H2R 0C2, CA
Employees at AbCellera
Updates
-
AbCellera Reports Q3 2024 Business Results https://ow.ly/8obQ50TZPCa
-
-
GPCRs hold immense promise as therapeutic targets, but their complexity has posed significant challenges for traditional antibody development. Visit our poster at #PEGSEurope to see how we generated and optimized multiple high-quality antibodies against a GPCR target. #biologics #antibodies #proteinengineering
-
-
Solid tumors account for more than 90% of cancers. Bringing effective TCEs to patients with these difficult-to-treat cancers requires tailored design strategies. Visit our poster at SITC to learn how diverse building blocks can be leveraged to widen the therapeutic window and enhance efficacy for this modality. https://lnkd.in/gZ8kf4QA #SITC24 #ImmunoOncology
-
-
AbCellera to Present at Upcoming Investor Conferences in November https://lnkd.in/gpN2TaFS
-
-
Learn about how novel CD3-binding antibodies could widen the therapeutic window for T-cell engagers by visiting our poster at Festival of Biologics in Basel. #FestivalOfBiologics #FOB2024 #TCellEngangers #Cancer
-
-
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 https://ow.ly/69xq50TE8rF
-
-
We’re excited to announce the publication of our review article in mAbs. The review highlights the critical aspects of developability assessment, and provides guidance on how to develop a comprehensive plan tailored to a given bispecific or multispecific to bring these innovative medicines to the clinic. Read the review here: https://ow.ly/u0qt50TwHNC
-
-
GPCRs are high-value targets that have been largely intractable to conventional antibody discovery technologies. Visit our poster at Discovery on Target to see how we generated and optimized multiple high-quality antibodies against a GPCR. #BostonDOT24 #drugtarget
-
-
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 https://lnkd.in/gWTMYpmm
-